drugset / Trial / NCT00523939
DepoCyt for Active Lymphomatous or Leukemic Meningitis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response rate of lymphomatous meningitis or leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well to the study drug, and the response of symptoms to the study drug will also be determined.
Timeline
- Start
- 2006-06
- Primary completion
- 2009-06
- Completion
- 2009-06
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 50 mg | Intrathecal |